Viewing Study NCT01593020

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:17 AM
Ignite Modification Date: 2026-01-12 @ 2:34 AM
Study NCT ID: NCT01593020
Status: COMPLETED
Last Update Posted: 2021-09-22
First Post: 2012-05-03
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast cancer View
None Early Stage Breast Cancer Not Overexpressing HER-2 View
None Primary invasive adenocarcinoma of the breast View
None Paclitaxel View
None Taxol View
None Eribulin View
None E7389 View
None 5-Fluorouracil View
None 5-FU View
None Adrucil View
None Efudex View
None Epirubicin View
None Ellence View
None Cyclophosphamide View
None Cytoxan View
None Neosar View
None Doxorubicin View
None Doxorubicin hydrochloride View
None Adriamycin PFS View
None Adriamycin RDF View
None Adriamycin View
None Rubex View